Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Controlled Phase IIa Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT05839639 is registered in ClinicalTrials.gov with Huahui Health as lead sponsor.

NCT NCT05839639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05839639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Controlled Phase IIa Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors
Lead sponsor
Huahui Health
Phase
Phase 2
Overall status
Completed
Start date
October 9, 2021
Completion date
May 17, 2023
Enrollment
73 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b